Recurrent Ovarian Cancer Clinical Trials 2023

Browse 72 Recurrent Ovarian Cancer Medical Studies Across 420 Cities
12 Phase 3 Trial · 1638 Recurrent Ovarian Cancer Clinics

Display Results

AllMost EffectiveMost SafeSenior FriendlyPediatricNo Placebo

Clinical Trials Recurrent Ovarian Cancer Clinical Trials 2023

Reviewed by Michael Gill, B. Sc.

Image of Magee-Womens Research Institute / UPMC Magee Womens Hospital in Pittsburgh, United States.

CPI-0209 (150 Mg) + Carboplatinfor Ovarian Cancer

This trial tests a new drug combo to treat ovarian cancer that's stopped responding to typical chemo.

Waitlist Available

Magee-Womens Research Institute / UPMC Magee Womens HospitalLan Coffman, MD, PhDMorphoSys AG

Image of AdventHealth Cancer Institute in Orlando, United States.

Olvimulogene Nanivacirepvecfor Ovarian Cancer

This trial is testing a new cancer treatment option for women with ovarian cancer that has stopped responding to other treatments.

AdventHealth Cancer Institute (+11 Sites)Robert W Holloway, MDGenelux Corporation

Image of University of Pittsburgh Medical Center in Pittsburgh, United States.

ZEN003694for Ovarian Cancer

This trial will study the safety and effectiveness of talazoparib and ZEN003694 in women with ovarian, fallopian tube, or primary peritoneal cancer that has come back or does not respond to treatment.

FDA Approved Drug

University of Pittsburgh Medical CenterHaider Mahdi, MDPfizer

Image of Regeneron Research Site in Tampa, United States.

REGN5668for Ovarian Cancer

This trial is testing the safety and efficacy of two drugs, REGN5668 and cemiplimab, in combination with each other or with another drug, REGN4018. The primary objective is to assess the safety and tolerability of the combinations and to determine the maximally tolerated dose. The secondary objectives are to assess the preliminary efficacy of the combinations and to characterize the safety profile and pharmacokinetics of the combinations.

FDA Approved Drug

Regeneron Research Site (+15 Sites)Clinical Trial ManagementRegeneron Pharmaceuticals

Image of Huntsman Cancer Institute in Salt Lake City, United States.

Ribociclibfor Breast Cancer

Salt Lake City, UT

This trial is designed to assess the maximum tolerated dose of two drugs, ribociclib and belinostat, in combination. The trial will start with a dose escalation, followed by an expansion cohort at the identified dose. Dose escalation will be open to patients with triple-negative breast cancer or ovarian cancer. Dose expansion will only be open to patients with triple-negative breast cancer.

FDA Approved Drug

Huntsman Cancer Institute (+1 Sites)Theresa Werner, MDNovartis

Image of UCLA / Jonsson Comprehensive Cancer Center in Los Angeles, United States.

Pembrolizumabfor Ovarian Cancer

Los Angeles, CA

This trial studies pembrolizumab to treat ovarian cancer that has come back. Monoclonal antibodies, like pembrolizumab, may help stop the growth and spread of cancer cells.

FDA Approved Drug

UCLA / Jonsson Comprehensive Cancer Center (+2 Sites)Gottfried KonecnyMerck Sharp & Dohme LLC

Image of Regeneron Study Site in Boston, United States.

REGN4018for Ovarian Cancer

This trial is studying REGN4018, given alone or together with cemiplimab, to see how well it works in treating patients with solid tumors that have spread (metastatic) or cannot be removed by surgery (unresectable).

FDA Approved Drug

Regeneron Study Site (+13 Sites)Clinical Trial ManagementRegeneron Pharmaceuticals

Image of Stanford University in Palo Alto, United States.

DPX-Survivacfor Ovarian Cancer

This trial will test the safety and potential effectiveness of combining three immunotherapy treatments for ovarian cancer.

Waitlist Available

FDA Approved Drug

Stanford University (+8 Sites)ImmunoVaccine Technologies, Inc. (IMV Inc.)

Image of Women's Cancer and Surgical Oncology Center in Loma Linda, United States.

Carboplatinfor Ovarian Cancer

This trial is comparing the effectiveness of two different treatments for ovarian, primary peritoneal, or fallopian tube cancer that has come back. One treatment is surgery to remove as much of the cancer as possible, followed by a single dose of chemotherapy given through the abdomen directly to the area where the cancer was. The other treatment is 6 cycles of standard chemotherapy given intravenously.

FDA Approved Drug

Women's Cancer and Surgical Oncology CenterMazdak Momeni, MD

Image of Duke Cancer Center in Durham, United States.

Oregovomabfor Ovarian Cancer

This trial is testing if a new combination of drugs can help people with ovarian cancer that has come back.

Waitlist Available

Duke Cancer Center (+2 Sites)Sunil Gupta, MD, FRCPCOncoQuest Pharmaceuticals Inc.

10 Recurrent Ovarian Cancer Clinical Trials Near Me

Top Hospitals for Recurrent Ovarian Cancer Clinical Trials

Image of M D Anderson Cancer Center in Texas.

M D Anderson Cancer Center

Houston

11Active Trials

0All Time Trials for Recurrent Ovarian Cancer

2014First Recurrent Ovarian Cancer Trial

Image of University of Colorado Hospital in Colorado.

University of Colorado Hospital

Aurora

9Active Trials

0All Time Trials for Recurrent Ovarian Cancer

2007First Recurrent Ovarian Cancer Trial

Image of Mayo Clinic in Rochester in Minnesota.

Mayo Clinic in Rochester

Rochester

8Active Trials

0All Time Trials for Recurrent Ovarian Cancer

2009First Recurrent Ovarian Cancer Trial

Image of University of Chicago Comprehensive Cancer Center in Illinois.

University of Chicago Comprehensive Cancer Center

Chicago

8Active Trials

0All Time Trials for Recurrent Ovarian Cancer

2009First Recurrent Ovarian Cancer Trial

Image of University of Pittsburgh Cancer Institute (UPCI) in Pennsylvania.

University of Pittsburgh Cancer Institute (UPCI)

Pittsburgh

8Active Trials

0All Time Trials for Recurrent Ovarian Cancer

2009First Recurrent Ovarian Cancer Trial

Top Cities for Recurrent Ovarian Cancer Clinical Trials

Image of Anchorage in Alaska.

Anchorage

43Active Trials

Alaska Women's Cancer CareTop Active Site

Image of Denver in Colorado.

Denver

42Active Trials

Porter Adventist HospitalTop Active Site

Recurrent Ovarian Cancer Clinical Trials by Phase of Trial

N/A Recurrent Ovarian Cancer Clinical Trials

1Active Recurrent Ovarian Cancer Clinical Trials

1Number of Unique Treatments

0Number of Active Locations

Quality-of-Life Assessment

Recurrent Ovarian Cancer Clinical Trials by Age Group

< 65 Recurrent Ovarian Cancer Clinical Trials

1Active Recurrent Ovarian Cancer Clinical Trials

Hyperthermic Intraperitoneal Chemotherapy

Most Recent Recurrent Ovarian Cancer Clinical Trials

Clinical Trial

Began Recruiting Date

Phase

Treatment (apheresis, FRalphaDC, pembrolizumab) for Fallopian Tube Carcinosarcoma

9/15/2023

Phase 1 & 2

CPI-0209 (150 mg) + carboplatin for Ovarian Cancer

9/1/2023

Phase 1

Treatment (SMMART-ACT) for Breast Cancer

9/1/2023

Phase < 1

Pembrolizumab for Ovarian Cancer

4/27/2023

Phase 2

Arm I (selumetinib, olaparib) for Endometrial Cancer

4/25/2023

Phase 2

Top Treatments for Recurrent Ovarian Cancer Clinical Trials

Treatment Name

Active Recurrent Ovarian Cancer Clinical Trials

All Time Trials for Recurrent Ovarian Cancer

First Recorded Recurrent Ovarian Cancer Trial

Pembrolizumab

4

4

2018

Bevacizumab

4

4

2007

Pharmacological Study

3

3

2009

Carboplatin

2

2

2016

Cisplatin

2

2

2014

About The Author

Michael Gill - B. Sc.

First Published: October 5th, 2021

Last Reviewed: August 3rd, 2023

References¹ Kirson ED, Dbalý V, Tovarys F, Vymazal J, Soustiel JF, Itzhaki A, Mordechovich D, Steinberg-Shapira S, Gurvich Z, Schneiderman R, Wasserman Y, Salzberg M, Ryffel B, Goldsher D, Dekel E, Palti Y. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10152-7. Epub 2007 Jun 5. https://pubmed.ncbi.nlm.nih.gov/17551011² Kirson ED, Gurvich Z, Schneiderman R, Dekel E, Itzhaki A, Wasserman Y, Schatzberger R, Palti Y. Disruption of cancer cell replication by alternating electric fields. Cancer Res. 2004 May 1;64(9):3288-95. https://pubmed.ncbi.nlm.nih.gov/15126372³ Kirson ED, Gurvich Z, Schneiderman R, Dekel E, Itzhaki A, Wasserman Y, Schatzberger R, Palti Y. Disruption of cancer cell replication by alternating electric fields. Cancer Res. 2004 May 1;64(9):3288-95. doi: 10.1158/0008-5472.can-04-0083. https://pubmed.ncbi.nlm.nih.gov/15126372⁴ Kirson ED, Dbaly V, Tovarys F, Vymazal J, Soustiel JF, Itzhaki A, Mordechovich D, Steinberg-Shapira S, Gurvich Z, Schneiderman R, Wasserman Y, Salzberg M, Ryffel B, Goldsher D, Dekel E, Palti Y. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10152-7. doi: 10.1073/pnas.0702916104. Epub 2007 Jun 5. https://pubmed.ncbi.nlm.nih.gov/17551011⁵ Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heidecke V, Kirson ED, Taillibert S, Liebermann F, Dbalý V, Ram Z, Villano JL, Rainov N, Weinberg U, Schiff D, Kunschner L, Raizer J, Honnorat J, Sloan A, Malkin M, Landolfi JC, Payer F, Mehdorn M, Weil RJ, Pannullo SC, Westphal M, Smrcka M, Chin L, Kostron H, Hofer S, Bruce J, Cosgrove R, Paleologous N, Palti Y, Gutin PH. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012 Sep;48(14):2192-202. doi: 10.1016/j.ejca.2012.04.011. Epub 2012 May 18. https://pubmed.ncbi.nlm.nih.gov/22608262⁶ Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heidecke V, Kirson ED, Taillibert S, Liebermann F, Dbaly V, Ram Z, Villano JL, Rainov N, Weinberg U, Schiff D, Kunschner L, Raizer J, Honnorat J, Sloan A, Malkin M, Landolfi JC, Payer F, Mehdorn M, Weil RJ, Pannullo SC, Westphal M, Smrcka M, Chin L, Kostron H, Hofer S, Bruce J, Cosgrove R, Paleologous N, Palti Y, Gutin PH. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012 Sep;48(14):2192-202. doi: 10.1016/j.ejca.2012.04.011. Epub 2012 May 18. https://pubmed.ncbi.nlm.nih.gov/22608262⁷ Kirson ED, Giladi M, Gurvich Z, Itzhaki A, Mordechovich D, Schneiderman RS, Wasserman Y, Ryffel B, Goldsher D, Palti Y. Alternating electric fields (TTFields) inhibit metastatic spread of solid tumors to the lungs. Clin Exp Metastasis. 2009;26(7):633-40. doi: 10.1007/s10585-009-9262-y. Epub 2009 Apr 23. https://pubmed.ncbi.nlm.nih.gov/19387848⁸ Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA; Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006 Jan 5;354(1):34-43. https://pubmed.ncbi.nlm.nih.gov/16394300⁹ Tattersall A, Ryan N, Wiggans AJ, Rogozińska E, Morrison J. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer. Cochrane Database Syst Rev. 2022 Feb 16;2:CD007929. doi: 10.1002/14651858.CD007929.pub4. Review. https://pubmed.ncbi.nlm.nih.gov/35170751¹⁰ Tattersall A, Ryan N, Wiggans AJ, Rogozinska E, Morrison J. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer. Cochrane Database Syst Rev. 2022 Feb 16;2(2):CD007929. doi: 10.1002/14651858.CD007929.pub4. https://pubmed.ncbi.nlm.nih.gov/35170751

Unbiased ResultsWe believe in providing patients with all the options.

Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.

Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.

Back to top

Terms of Service Privacy Policy Security